Next Article in Journal
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
Next Article in Special Issue
Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients
Previous Article in Journal
CD83, a Novel MAPK Signaling Pathway Interactor, Determines Ovarian Cancer Cell Fate
Previous Article in Special Issue
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
Open AccessArticle

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy

1
Department of Urology, University Hospitals Leuven, Leuven 3000, Belgium
2
Department of Radiation Oncology, University Hospitals Leuven, Leuven 3000, Belgium
3
Department of Nuclear Medicine, University Hospitals Leuven, Leuven 3000, Belgium
4
Department of Radiology, University Hospitals Leuven, Leuven 3000, Belgium
*
Authors to whom correspondence should be addressed.
Both authors should be considered as senior author.
Cancers 2020, 12(8), 2271; https://doi.org/10.3390/cancers12082271
Received: 6 July 2020 / Revised: 3 August 2020 / Accepted: 4 August 2020 / Published: 13 August 2020
(This article belongs to the Special Issue Recent Scientific Developments in Metastatic Prostate Cancer)
Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer (mCRPC)-free survival as long-term oncological outcomes in oligorecurrent PCa treated by MDT. We retrospectively identified consecutive post-prostatectomy oligorecurrent PCa patients treated by MDT (salvage lymphadenectomy, radiotherapy, or metastasectomy) at our tertiary referral center. Patients were eligible for inclusion if they developed recurrence following radical prostatectomy, had ≤5 metastatic lesions on imaging and had a serum testosterone >50 ng/dL or a testosterone suppression therapy-free interval of >2 years prior to the first MDT as an assumption of recovered serum testosterone (if no testosterone measurement available). Patients with castration-resistant or synchronous oligometastatic PCa at the time of first MDT were excluded. Repeated MDTs were allowed, as well as a period of concomitant ADT. Kaplan–Meier analyses were performed to assess palliative ADT-free and mCRPC-free survival. We identified 191 eligible patients who underwent MDT. Median follow-up from first MDT until last follow-up or death was 45 months (IQR 27–70; mean 51 months). Estimated median palliative-ADT free survival was 66 months (95% CI 58–164) and estimated median mCRPC-free survival was not reached (mean 117 months, 95% CI 103–132). In total, 314 MDTs were performed and 25 patients (13%) received ≥3 MDTs. This study demonstrated that (repeated) MDT is feasible and holds promise in terms of palliative ADT-free and mCRPC-free survival for patients with oligorecurrent PCa. However, these findings should be confirmed in prospective randomized controlled trials. View Full-Text
Keywords: metastasis directed therapy; oligometastatic prostate cancer; oligorecurrent prostate cancer; metastasectomy; SBRT; salvage lymphadenectomy metastasis directed therapy; oligometastatic prostate cancer; oligorecurrent prostate cancer; metastasectomy; SBRT; salvage lymphadenectomy
Show Figures

Figure 1

  • Supplementary File 1:

    DOCX-Document (DOCX, 340 KB)

  • Externally hosted supplementary file 1
    Doi: /
    Link: http:///
    Description: /
MDPI and ACS Style

Devos, G.; Berghen, C.; Van Eecke, H.; Stichele, A.V.; Van Poppel, H.; Goffin, K.; Mai, C.; De Wever, L.; Albersen, M.; Everaerts, W.; De Meerleer, G.; Joniau, S. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy. Cancers 2020, 12, 2271.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop